ARQT vs. ROIV, RVMD, LNTH, LEGN, TGTX, BBIO, AXSM, TLX, BPMC, and GRFS
Should you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), TG Therapeutics (TGTX), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.
Arcutis Biotherapeutics vs.
Arcutis Biotherapeutics (NASDAQ:ARQT) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
In the previous week, Roivant Sciences had 4 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 15 mentions for Roivant Sciences and 11 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.23 beat Roivant Sciences' score of 0.74 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.
Arcutis Biotherapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.
Arcutis Biotherapeutics received 14 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.26% of users gave Roivant Sciences an outperform vote while only 66.67% of users gave Arcutis Biotherapeutics an outperform vote.
64.8% of Roivant Sciences shares are held by institutional investors. 9.5% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 7.9% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Roivant Sciences has lower revenue, but higher earnings than Arcutis Biotherapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Roivant Sciences has a net margin of -119.54% compared to Arcutis Biotherapeutics' net margin of -140.97%. Roivant Sciences' return on equity of -14.05% beat Arcutis Biotherapeutics' return on equity.
Arcutis Biotherapeutics presently has a consensus target price of $18.80, indicating a potential upside of 14.15%. Roivant Sciences has a consensus target price of $17.10, indicating a potential upside of 63.79%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Arcutis Biotherapeutics.
Summary
Roivant Sciences beats Arcutis Biotherapeutics on 12 of the 19 factors compared between the two stocks.
Get Arcutis Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcutis Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ARQT) was last updated on 3/27/2025 by MarketBeat.com Staff
Buy ARQT Stock Free ARQT Stock Alerts